查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362979

光化性角化症治療市場規模、佔有率和趨勢分析報告：2023-2030 年按治療、藥物類別、最終用途、地區和細分市場進行的預測

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10個工作天內

價格

光化性角化症治療市場的成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球光化性角化病治療市場規模將達到89億美元，2023年至2030年年複合成長率為4.3%。

由於光化性角化病藥物的廣泛使用、對該疾病的認知不斷提高以及 AK 治療數量的增加等要素，預計該市場將出現成長機會。此外，全球光化性角化病患患病的增加和老年人口的增加預計將在預測期內推動市場成長。

AK 惡性化（iSCC）後可發展為惡性鱗狀細胞癌。儘管 iSCC 有多種潛在原因，但 AK 是最常見的原因之一。此外，基底細胞癌和非黑色素瘤皮膚癌也可能由 AK 引起。因此，光化性角化症的早期診斷和治療作為預防併發症的策略，推動了整個銷售管道對 AK 產品的需求。

此外，越來越多的未來管道藥物和聯合治療正在促進因素市場發展。例如，南澳 Almirall 的 Klisyri（擴大適應症）處於 III 期研究和開發階段。此外，創新藥物的接受度和商業化程度的提高是預計推動市場成長的另一個要素。此外，研發活動的活性化預計將加速用於治療光化性角化症的新藥的核准，從而推動預測期內的成長。

主要企業正在採取產品發布、聯盟和擴大策略等策略舉措，以增加市場佔有率。例如，2022 年 6 月，BIOFRONTERA AG 宣布，總部位於瑞士的 Louis Widmer SA 已獲得 Ameluz 治療身體軀幹、四肢和頸部光化性角化病的行銷核准延期。此外，BIOFRONTERA AG 於 2020 年 7 月宣布，已與 Galenica AB 簽署協議，在挪威、芬蘭、挪威和冰島分銷 BF-RhodoLED 和 Ameluz。

光化性角化症治療市場報告亮點

  • 2022 年，由於擴大採用冷凍療法治療光化性角化病，外科手術佔據了最大的銷售佔有率，達到 65.6%。
  • 核苷代謝抑制劑在2022年佔據最大的收益佔有率，為32.4%，預計在預測期內將保持其主導地位。
  • 由於 AK患病、醫療基礎設施快速發展以及亞太國家醫療保健支出增加等要素，預計亞太地區在預測期內將以 5.6%的年複合成長率成長最快。
  • 由於公眾對光化性角化病的認知提高、有效治療方案的可用性以及醫療基礎設施的改善，北美在 2022 年以 41.5% 的最大銷售佔有率佔據市場主導地位。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 光化性角化症治療市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 光化性角化症治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 光化性角化症治療市場：治療估計與趨勢分析

  • 光化性角化症治療市場：重點
  • 光化性角化症治療市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 局部的
  • 外科手術
  • 光動力療法

第5章 光化性角化症治療市場：藥物類別估計與趨勢分析

  • 光化性角化症治療市場：重點
  • 光化性角化症治療市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 核苷代謝抑制劑
  • NSAIDS
  • 免疫反應調節劑
  • 照片增強劑
  • 其他

第6章 光化性角化症治療市場：最終用途估計與趨勢分析

  • 光化性角化症治療市場：重點
  • 光化性角化症治療市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 醫院
  • 私人診所
  • 居家護理
  • 其他

第7章 光化性角化症治療市場：區域估計與趨勢分析

  • 區域展望
  • 光化性角化症治療市場（按地區）：要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Almirall SA
    • LEO Pharma A/S
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • GALDERMA
    • Ortho Dermatologics (Bausch Health Companies Inc.)
    • BIOFRONTERA AG
    • Hill Dermaceuticals, Inc.
Product Code: GVR-2-68038-940-1

Actinic Keratosis Treatment Market Growth & Trends:

The global actinic keratosis treatment market size is expected to reach USD 8.9 billion by 2030, registering a CAGR of 4.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, Norway, and Iceland.

Actinic Keratosis Treatment Market Report Highlights:

  • Surgery held the largest revenue share of 65.6% in 2022 owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis
  • Nucleoside metabolic inhibitors held the largest revenue share of 32.4% in 2022 and is expected to retain its dominance over the forecast period
  • Asia Pacific is expected to grow at the fastest CAGR of 5.6% during the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries
  • North America dominated the market with the largest revenue share of 41.5% in 2022 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapy
    • 1.1.2. Drug class
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Actinic Keratosis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 4.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Topical
    • 4.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Photodynamic Therapy
    • 4.5.1. Photodynamic therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 5.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside Metabolic Inhibitor
    • 5.3.1. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. NSAIDS
    • 5.4.1. NSAIDS market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Immune Response Modifiers
    • 5.5.1. Immune response modifiers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Photoenhancers
    • 5.6.1. Photoenhancers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End-use Estimates & Trend Analysis

  • 6.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 6.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Private Clinics Delivery
    • 6.4.1. Private clinics delivery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Homecare
    • 6.5.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Actinic Keratosis Treatment Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Almirall S.A.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. LEO Pharma A/S
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Sun Pharmaceutical Industries Ltd.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Novartis AG
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. GALDERMA
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Ortho Dermatologics (Bausch Health Companies Inc.)
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. BIOFRONTERA AG
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hill Dermaceuticals, Inc.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives 

List of Tables

  • 1. List of Abbreviations
  • 2. North America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 3. North America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 4. North America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 5. North America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 6. U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 7. U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 8. U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 9. Canada actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 10. Canada actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 11. Canada actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 12. Europe actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 13. Europe actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 14. Europe actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 15. Europe actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 16. Germany actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 17. Germany actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 18. Germany actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 19. UK actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 20. UK actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 21. UK actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 22. France actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 23. France actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 24. France actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 25. Italy actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 26. Italy actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 27. Italy actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 28. Spain actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 29. Spain actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 30. Spain actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 31. Sweden actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 32. Sweden actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 33. Sweden actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 34. Norway actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 35. Norway actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 36. Norway actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 37. Denmark actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 38. Denmark actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 39. Denmark actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 40. Asia Pacific actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 41. Asia Pacific actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 42. Asia Pacific actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 43. Asia Pacific actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 44. China actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 45. China actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 46. China actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 47. Japan actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 48. Japan actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 49. Japan actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 50. India actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 51. India actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 52. India actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 53. Thailand actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 54. Thailand actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 55. Thailand actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 56. South Korea actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 57. South Korea actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 58. South Korea actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 59. Latin America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 60. Latin America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 61. Latin America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 62. Latin America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 63. Brazil actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 64. Brazil actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 65. Brazil actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 66. Mexico actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 67. Mexico actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 68. Mexico actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 69. Argentina actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 70. Argentina actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 71. Argentina actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 72. Middle East and Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 73. Middle East and Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 74. Middle East and Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 75. Middle East and Africa actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 76. South Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 77. South Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 78. South Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 79. Saudi Arabia actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 80. Saudi Arabia actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 81. Saudi Arabia actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 82. UAE actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 83. UAE actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 84. UAE actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 85. Kuwait actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 86. Kuwait actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 87. Kuwait actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • 1. Market research process
  • 2. Data triangulation techniques
  • 3. Primary research pattern
  • 4. Market research approaches
  • 5. Value-chain-based sizing & forecasting
  • 6. QFD modeling for market share assessment
  • 7. Market formulation & validation
  • 8. Actinic keratosis treatment: Market outlook
  • 9. Actinic keratosis treatment: Competitive insights
  • 10. Parent market outlook
  • 11. Related/ancillary market outlook
  • 12. Penetration and growth prospect mapping
  • 13. Industry value chain analysis
  • 14. Actinic keratosis treatment market driver impact
  • 15. Actinic keratosis treatment market restraint impact
  • 16. Actinic keratosis treatment market strategic initiatives analysis
  • 17. Actinic keratosis treatment market: Therapy movement analysis
  • 18. Actinic keratosis treatment market: Therapy outlook and key takeaways
  • 19. Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 20. Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 21. Photodynamic therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 22. Actinic keratosis treatment market: Drug class movement analysis
  • 23. Actinic keratosis treatment market: Drug class outlook and key takeaways
  • 24. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 25. NSAIDS market estimates and forecasts, 2018 - 2030 (USD Million)
  • 26. Immune response modifiers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 27. Photoenhancers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 28. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 29. Actinic keratosis treatment market: End-use movement analysis
  • 30. Actinic keratosis treatment market: End-use outlook and key takeaways
  • 31. Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • 32. Private clinics delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 33. Homecare market estimates and forecasts, 2018 - 2030 (USD Million)
  • 34. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 35. Global actinic keratosis treatment market: Regional movement analysis
  • 36. Global actinic keratosis treatment market: Regional outlook and key takeaways
  • 37. North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 38. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 39. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 40. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • 41. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 42. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 43. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 44. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 45. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 46. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 47. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 48. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 49. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • 50. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 51. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 52. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 53. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 54. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 55. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 56. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 57. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 58. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 59. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 60. Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 61. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 62. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 63. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 64. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)